Physician profile
Christianah Y Ogunlesi
NPI 1063507358
$9,709.90
in general payments reported to CMS, 2019-2025
21 companies · $3,042 in 2025
The $3,042 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $709 · 2021: $640 · 2022: $1,297 · 2023: $1,511 · 2024: $1,971 · 2025: $3,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,523.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,729.70 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,714.55 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $1,620.28 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $1,408.12 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,044.96 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $919.75 | 2020-2025 | Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $301.39 | 2024-2025 | Cobenfy |
| Abbvie INC. | $246.88 | 2024-2025 | |
| Indivior INC. | $147.87 | 2020-2024 | Perseris |
| Axsome Therapeutics, INC. | $124.97 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.22 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $56.60 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $51.94 | 2025 | Invega Sustenna, Spravato |
| Bioxcel Therapeutics, INC. | $49.09 | 2023 | Igalmi |
| Braeburn INC. | $42.72 | 2025 | Brixadi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $40.73 | 2022 | |
| Beckman Coulter, INC. | $36.61 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.41 | 2025 | Abilify Asimtufii |
| Luye Pharma (USA) LTD. | $24.11 | 2025 | Erzofri Extended-Release |
| Corium, LLC | $23.23 | 2023 | Azstarys |
| Neuronetics, INC. | $22.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christianah Ogunlesi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.